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Akt ( protein kinase B), a subfamily of the AGC ser-
ine/threonine kinases, plays critical roles in survival,
proliferation, glucose metabolism, and other cellular
functions. Akt activation requires the recruitment of the
enzyme to the plasma membrane by interacting with
membrane-bound lipid products of phosphatidylinositol
3-kinase. Membrane-bound Akt is then phosphorylated
at two sites for its full activation; Thr-308 in the activa-
tion loop of the kinase domain is phosphorylated by
3-phosphoinositide-dependent kinase-1 (PDK1) and Ser-
473 in the C-terminal hydrophobic motif by a putative
kinase PDK2. The identity of PDK2 has been elusive.
Here we present evidence that conventional isoforms of
protein kinase C (PKC), particularly PKCII, can regu-
late Akt activity by directly phosphorylating Ser-473 in
vitro and in IgE/antigen-stimulated mast cells. By con-
trast, PKC is not required for Ser-473 phosphorylation
in mast cells stimulated with stem cell factor or inter-
leukin-3, in serum-stimulated fibroblasts, or in antigen
receptor-stimulated T or B lymphocytes. Therefore,
PKCII appears to work as a cell type- and stimulus-
specific PDK2.
Akt is a subfamily of the AGC serine/threonine kinases con-
sisting of Akt1/PKB, Akt2/PKB, and Akt3/PKB. These ki-
nases have an N-terminal pleckstrin homology domain fol-
lowed by a C-terminal kinase catalytic domain. Numerous
studies implicate Akt in survival, proliferation, and glucose
metabolism (reviewed in Refs. 1–3). Akt activation requires the
recruitment of the enzyme to the plasma membrane through
the interaction of the pleckstrin homology domain with plasma
membrane-bound lipid products of phosphatidylinositol 3-ki-
nase, i.e. phosphatidylinositol 3,4,5-trisphosphate and phos-
phatidylinositol 3,4-bisphosphate (4–7). Membrane-bound Akt
is then phosphorylated at two sites for full activation (8); Thr-
308 in the activation loop of the kinase domain is phosphoryl-
ated by PDK11 (5, 7, 9) and Ser-473 in the C-terminal hydro-
phobic motif by a putative kinase PDK2. The identity of PDK2
has been controversial (10), although several PDK2 candidates
including integrin-linked kinase (ILK) (11, 12) and autophos-
phorylation (13) have been proposed.
PKC is also a subfamily of the AGC serine/threonine kinases,
which are involved in proliferation, differentiation, metabo-
lism, and cell-type specific functions (14, 15). Based on struc-
tural features and cofactor requirements, PKC isoforms are
classified into three categories; conventional or classical iso-
forms (cPKCs: , I, II, and ) depend on diacylglycerol (DAG)
and Ca2 for their activation, novel isoforms (nPKCs: , , ,
and ) depend on DAG, but not Ca2, and atypical isoforms
(atypical PKC isoforms:  and 	/
) do not require either DAG or
Ca2.
Cross-linking of high-affinity IgE receptors (FcRI) ex-
pressed on the surface of mast cells activates Akt (16) and
various PKC isoforms including PKCI and PKCII (17). Im-
portantly, Akt in mast cells is involved in FcRI-induced pro-
duction of cytokines such as IL-2 through the activation of such
transcription factors as NF-B, NF-AT, and AP-1 (16), and
PKC is also required for FcRI-induced degranulation and
cytokine production (18). In the present study we have found
that cPKC isoforms, particularly PKCII, can regulate Akt
activity by directly phosphorylating the critical residue Ser-473
in vitro and in FcRI-stimulated mast cells. By contrast, PKC
is not required for Ser-473 phosphorylation in mast cells stim-
ulated with stem cell factor (SCF) or IL-3, in serum-stimulated
fibroblasts, or in antigen receptor-stimulated T or B cells.
Therefore, PKCII functions as a cell type- and stimulus-spe-
cific PDK2.
EXPERIMENTAL PROCEDURES
Antibodies and Recombinant Proteins—Anti-FcRI  subunit mono-
clonal antibody JRK was originally donated by Dr. Juan Rivera, Na-
tional Institutes of Health. Commercial sources of antibodies used were:
anti-Akt (C-20), anti-PKC (C-20), anti-PKCI (C-16), anti-PKCII (C-
18), anti-PKC (C-15), anti-PKC (C-19), anti-PKC (C-20), and anti-
Vav (C-14) from Santa Cruz Biotechnology; anti-phospho-PKC (pan), a
gift from Dr. Michael Comb; anti-Akt(pThr308), Akt(pS473), anti-BAD,
and anti-GSK-3(pS21) from Cell Signaling Technology; anti-HA
(12CA5) from Roche Applied Science; anti-ILK and anti-c-Raf1 from
Upstate Cell Signaling Solutions; and anti-FLAG from Kodak Scientific
Imaging Systems. Recombinant PKC, PKCI, PKCII, and PKC
were from Invitrogen, and recombinant Akt was from Upstate Cell
Signaling Solutions.
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Supplemental Material can be found at: 
Cells and Stimulation—Bone marrow cells derived from wild-type
(wt), PKC/ (19), PKC/ (20), and PKC/ (21) mice were
cultured in IL-3-containing medium for 4–6 weeks to generate 95%
pure populations of mast cells (BMMC). Fetal liver cells were cultured
in medium containing IL-3 and mouse recombinant SCF for 4–6 weeks
to generate similarly pure populations of mast cells (FLMC). Mast cells
cultured in SCF for more than a week are labeled as SCF-BMMC or
SCF-FLMC. Mast cells were sensitized overnight with anti-dinitrophe-
nyl (DNP) IgE monoclonal antibody and stimulated with the antigen,
DNP-human serum albumin conjugates, unless otherwise mentioned.
Fibroblasts were cultured from 15–18 day embryos of PKC/,
PKC/, and PKC/ genotypes as described previously (22).
Retroviral transduction of PKC/ mast cells was done as de-
scribed previously (23). Briefly, pMX-puro plasmids harboring wt or
mutant PKCI, PKCII, or HA-tagged Akt cDNAs were transfected
into packaging cells to generate recombinant retroviruses. BMMC in
culture medium containing IL-3 and SCF were infected with the vi-
ruses. Mass populations of puromycin-resistant cells were used for
FcRI stimulation. PKC knock-down constructs consisted of pSUPER.
retro (OligoEngine) vectors containing the oligonucleotides that could be
double-stranded with a loop-out. These vectors were transfected into
NIH/3T3 cells to test their ability to suppress PKC expression. The best
vector was selected by immunoblotting and used to generate recombinant
retrovirus, and the virus was used to infect wt and PKC/ BMMC.
Immunoblotting Analysis—Subcellular fractionation was performed
as described previously (24). Otherwise, cells were lysed in 1% Nonidet
P-40-containing lysis buffer. Proteins in cleared cell lysates or subcel-
lular fractions were either immunoprecipitated before, or directly ana-
lyzed by, SDS-PAGE followed by electroblotting onto polyvinylidene
difluoride membranes (Millipore).
In Vitro Kinase Assays—Protein kinases either in immunoprecipi-
tated or purified forms were incubated with synthetic peptide or recom-
binant protein substrate in the presence of [-32P]ATP. Reaction prod-
ucts were analyzed by SDS-PAGE and autoradiography. Alternatively,
reaction mixtures were spotted onto P81 phosphocellulose filters, and
the radioactivity of filters after washing in phosphoric acid was quan-
tified. Synthetic peptides used in in vitro kinase assays were prepared
in-house or purchased from A& A Laboratories (S473tide and T308tide)
or from Upstate (Crosstide), and their sequences are as follows: 1)
ECVDSERRPHFPQFSYSASSTA (the underlined S indicates Ser-473,
in single-letter amino acid code), used in Ser-473 phosphorylation ex-
periments (Fig. 2a); 2) S473tide for Ser-473 phosphorylation: RRPHF-
PQFSYSA (Ser-473 is underlined); 3) T308tide for Thr-308 phosphoryl-
ation: KTFCGTPEYLAPEVRR (Thr-308 is underlined); Crosstide for
Akt assay: GRPTSSFAEG.
Measurement of Histamine and Cytokines—IgE-sensitized cells were
stimulated with antigen. Histamine secreted for 45 min was measured
by on-column high performance liquid chromatography. IL-2 and tumor
necrosis factor- secreted for 20 h were quantified by enzyme-linked
immunosorbent assay kits (Pharmingen).
RESULTS
Akt Is Phosphorylated in Response to Phorbol Ester and
Interacts Physically with cPKC Isoforms in Mast Cells—We
first tested whether Akt phosphorylation can be induced by
phorbol ester, a DAG analogue. Immunoblot analysis of BMMC
derived from wt mice demonstrated that phorbol 12-myristate
13-acetate (PMA) rapidly induces Akt phosphorylation on Ser-
473 (Fig. 1a), suggesting that PMA-responsive PKC (conven-
tional and/or novel) isoforms can activate Akt. Interestingly,
Ser-473 phosphorylation was substantially reduced in BMMC
from PKC/ mice. We then assessed whether Akt is physi-
cally associated with such PKCs. Immunoblotting of Akt im-
munoprecipitates showed that cPKCs (i.e. , I, and II.  is
not expressed in BMMC) were coprecipitated with Akt, and
PKCII association was particularly robust and inducible by
FcRI stimulation with IgE and antigen (Fig. 1b). Conversely,
Akt was detected in immune complexes precipitated by anti-
PKC, anti-PKCI, or anti-PKCII (data not shown), and these
interactions were direct (supplementary Fig. S1). A small
amount of ILK was also coimmunoprecipitated with Akt. By
contrast, PKC, PKC, PKC, or c-Raf1 was not detected in Akt
immunoprecipitates, although these kinases were abundantly
expressed in mast cells.
cPKC Isoforms Can Phosphorylate Akt on Ser-473 in Vitro—
Given the physical association between Akt and cPKCs, we
examined whether Akt serves as a phosphorylation target for
cPKC isoforms. First, we tested whether synthetic peptides
corresponding to the Akt C-terminal 22 residues encompassing
Ser-473 can be phosphorylated by recombinant PKC, PKCI,
and PKCII. The non-phosphorylated (NP) peptide (or
S473tide) was phosphorylated by these kinases with an order of
PKC  PKCII  PKCI in potency (Fig. 2a), while the
Ser-473-phosphorylated (pS) peptide was not phosphorylated
by any of these isoforms despite the presence in this peptide of
four Ser and one Thr residues as potential phosphorylation
sites. We then tested whether these cPKCs can phosphorylate
Akt. As shown in Fig. 2b, Akt was not phosphorylated on
Thr-308 by these PKC isoforms, although the latter enzymes
phosphorylated themselves on Thr-497 (PKC) or Thr-500
(PKCI and PKCII) in their activation loop under the same
conditions. Strikingly, Akt Ser-473 was phosphorylated by
PKC and PKCII in a concentration-dependent manner (Fig.
2b). Ser-473 phosphorylation by PKCI was weaker and satu-
rated at lower levels than that by PKC or PKCII and did not
correlate with its autophosphorylating potency. These results
indicate that the cPKCs, particularly PKC and PKCII, have
a vigorous PDK2 activity in vitro and they can phosphorylate
Akt on Ser-473 without prior phosphorylation on Thr-308, con-
sistent with previous studies showing that Ser-473 phospho-
rylation is independent of Thr-308 phosphorylation (8, 25, 26).
Akt Catalytic Activity and Ser-473 Phosphorylation Are Re-
duced in FcRI-stimulated PKC/ Mast Cells—BMMC are
immature mast cells widely used for studies of FcRI signal
FIG. 1. Akt is phosphorylated by phorbol ester and interacts
physically with cPKC isoforms in mast cells. a, wt and PKC/
BMMC were stimulated by 100 nM PMA for the indicated periods. Cell
lysates were analyzed by immunoblotting with anti-Akt(pS473). The
blots were reprobed with anti-Akt. b, MCP-5 mouse mast cells were
sensitized overnight with anti-DNP IgE and stimulated by 100 ng/ml
DNP-human serum albumin for the indicated periods. Cleared cell
lysates were immunoprecipitated with goat anti-Akt antibody or nor-
mal goat IgG (NGG) and immune complexes analyzed by immunoblot-
ting with antibodies for the indicated proteins. The blots were stripped
and reprobed with anti-Akt. Ag, antigen.
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transduction. Cell surface expression of FcRI and c-Kit was
comparable between wt and PKC/ BMMC, and cell viabil-
ity was not affected by PKC deficiency (data not shown).
Antigen stimulation of IgE-sensitized wt BMMC induced Ser-
473 phosphorylation (Fig. 3a). Remarkably, Akt Ser-473 phos-
phorylation levels were lower in unstimulated PKC/
BMMC than in unstimulated wt cells, and IgE/antigen-induced
peak Ser-473 phosphorylation levels were also drastically (50–
80%) reduced in PKC/ BMMC at all antigen concentra-
tions tested. Similar, but more dramatic, reduction was ob-
served in IgE/antigen-stimulated PKC/ cells (Fig. 3a,
lower panel (the SCF-FLMC part), and data not shown) when
BMMC and FLMC that had been cultured in the presence of
SCF were used. SCF induces maturation of immature mast
cells. Consistent with a significant role for Ser-473 phosphoryl-
ation in Akt activation, Akt activation induced by IgE/antigen
stimulation, as assessed by its ability to phosphorylate its
substrate, BAD or Crosstide, was also reduced in PKC/
BMMC (Fig. 3, b and c). By contrast, FcRI-induced Ser-473
phosphorylation was not reduced in PKC/ or PKC/
BMMC compared with their wt controls (supplementary Fig.
S2), although these nPKC isoforms are expressed in BMMC.
These results, together with the reduced Ser-473 phosphoryl-
ation in PMA-stimulated PKC/ BMMC (Fig. 1a), demon-
strate the selective ability of PKC relative to the nPKC iso-
forms to regulate Ser-473 phosphorylation in mast cells.
Consistent with previous results that Ser-21 of GSK-3 is a
phosphorylation target of Akt (27, 28), Ser-21 phosphorylation
was substantially reduced in PKC/ BMMC (Fig. 3d).
Reconstitution with PKCII, but Not PKCI, Can Restore
FcRI-induced Akt Ser-473 Phosphorylation and IL-2 Produc-
tion in PKC-deficient Mast Cells—PKCI and PKCII were
generated by alternative splicing (29), and PKC/mice lack
the expression of both isoforms. To test whether defects in Akt
phosphorylation and activity in PKC/ BMMC are direct
effects of the deficiency of PKCI and/or PKCII, we reconsti-
tuted these cells with PKCI or PKCII by retroviral transduc-
tion. Under the current transduction experiments, which re-
quire SCF to drive cell cycling to promote retroviral integration
in BMMC leading to further differentiation of mast cells, Akt
phosphorylation on Thr-308 was minimally affected by PKC
deficiency (see the rightmost eight lanes in Fig. 4a), although
reconstitution with either PKCI or PKCII enhanced Thr-308
phosphorylation in PKC/ cells. The increased Thr-308
phosphorylation seemed to be due to overexpression of PKCI
or PKCII. Indeed, immunoblot analysis using recombinant
PKCI and PKCII as a reference revealed overexpression of
PKCI and PKCII in the reconstituted cells (wt PKCI, 200
ng/106 cells; kinase-dead (KD) PKCI, 50 ng; wt PKCII, 250
ng; KD PKCII, 19 ng in reconstituted cells versus PKCI,
1.25 ng; PKCII, 50 ng in non-transfected wt BMMC). Recon-
stitution with wt PKCII restored Ser-473 phosphorylation to a
full extent, while reconstitution with wt PKCI at comparable
expression levels failed to do so (Fig. 4b). By contrast, expres-
sion of KD mutants of PKCI or PKCII in PKC/ cells
failed to reconstitute Akt phosphorylation, indicating that the
catalytic activity of PKCII is required for Ser-473 phosphoryl-
ation. Taking into consideration our immunoblotting data that
the BMMC used express 40-fold more PKCII (50 ng/106 cells)
than PKCI (1.25 ng/106 cells), these results (Fig. 4b) and the
stronger in vitro Ser-473 phosphorylating activity of PKCII
versus PKCI (Fig. 2, a and b) suggest that Ser-473 phospho-
rylation and hence Akt catalytic activity are mainly under
control of the enzymatic activity of PKCII in FcRI-stimulated
BMMC. Another potential interpretation of the reconstitution
experiments, which does not contradict the notion of PKCII-
dependent Akt regulation is that PKC expression permits
mast cell precursors to respond better to SCF or IL-3. However,
there is no indication that PKC is involved in SCF or IL-3
signaling (Ref. 18 and data not shown).
Although a reduction in Thr-308 phosphorylation in
PKC/ cells was much smaller than that in Ser-473 phos-
phorylation, there is a possibility that autophosphorylation of
Akt contributes to Ser-473 phosphorylation (13) in mast cells.
To assess this possibility, we sought to measure Ser-473 phos-
phorylating activity of PKCII under conditions that minimize
the autophosphorylation of the transduced Akt. We transduced
wt and PKC/ BMMC with a HA-tagged KD (K179M) Akt
mutant. For a comparison, HA-tagged wt Akt and T308A mu-
tant Akt were also transduced. Ser-473 phosphorylation of
HA-tagged wt and T308A was reduced in PKC/ cells com-
pared with wt cells (Fig. 4c), just like that of endogenous Akt
protein in non-transfected cells. Importantly, Ser-473 phospho-
rylation of HA-tagged K179M Akt was robustly induced in wt
cells upon FcRI stimulation (Fig. 4c), ruling out the possibility
that Ser-473 phosphorylation is a result of mainly autophos-
phorylation. By contrast, Ser-473 phosphorylation of HA-
tagged K179M Akt was almost abrogated in PKC/ cells
(Fig. 4c). These results indicate that Ser-473 is predominantly
phosphorylated by PKCII in FcRI-stimulated mast cells. Ex-
periments using protein phosphatase inhibitors indicate that
dephosphorylation at Ser-473 is not regulated by PKC (sup-
plementary Fig. S3a).
Because the evidence described above indicates that PKCII
is a major PDK2 in FcRI-stimulated mast cells, we determined
kinetic parameters of S473tide phosphorylation by PKCII.
The Km and Vmax values were in a similar range as those for
T308tide phosphorylation by PDK1 (Km  873.6  250.7 M;
Vmax  77,286  7,767 mol/min for S473tide phosphorylation
by PKCII versus Km  933.1  261.9 M; Vmax  20,100 
2,027 mol/min for T308tide phosphorylation by PDK1), sup-
porting the physiological relevance of our in vitro data. To
further address the physiological relevance of PKCII-medi-
ated Akt regulation, PKC/ BMMC transduced with PKCI
or PKCII were stimulated with IgE and antigen. The cells
reconstituted with either PKCI or PKCII released histamine
as well as did the wt BMMC (Fig. 5a). Reconstitution with wt
FIG. 2. PMA-responsive cPKCs can phosphorylate on Ser-473
in vitro. a, recombinant PKC, PKCI, PKCII, and PKC (0.1 g per
reaction) were incubated with 2 g each of synthetic non-phosphoryl-
ated (NP) or Ser-473-phosphorylated (pS) Akt C-terminal peptides in
the presence of [-32P]ATP. Reaction products were analyzed by SDS-
PAGE and autoradiography. b, unactivated recombinant Akt (0.2 g
per reaction) was incubated with the indicated amounts of recombinant
PKC, PKCI, or PKCII under the kinase assay conditions in the
presence of cold ATP. Reaction products were analyzed by immunoblot-
ting with anti-Akt(pT308) and anti-Akt(pS473). The same blot was
reprobed with anti-PKC (pT500) that reacts with Thr-497-phosphoryl-
ated PKC and Thr-500-phosphorylated PKCI and PKCII.
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PKCII robustly restored IL-2 production in PKC/ BMMC,
whereas that with PKCI did not (Fig. 5b). Consistent with the
role of Akt in FcRI-induced IL-2 production (16), these results
indicate that PKCII-dependent Akt activation is crucial for
FcRI-induced IL-2 production.
PKC Is Not a Major Regulator of Akt Ser-473 Phosphoryl-
ation in FcRI-stimulated Mast Cells—Given the strong in vitro
PDK2 activity of PKC (Fig. 2, a and b) and without access to
PKC/ mice, we tested effects of small interfering RNA-
mediated PKC knock-down on Akt phosphorylation. PKC
knock-down did not significantly affect Ser-473 phosphoryla-
tion in wt or PKC/ BMMC (supplementary Fig. S4a). Fur-
thermore, Go¨-6976 (cPKC inhibitor) treatment of PKC/
BMMC minimally affected Ser-473 phosphorylation, whereas
the same treatment substantially reduced it in wt BMMC
(supplementary Fig. S4b). These results are consistent with the
predominant role of PKCII as the PDK2 among the cPKCs
expressed in FcRI-stimulated mast cells.
PKC-mediated Akt Ser-473 Phosphorylation Is Dependent
on Stimulus and Cell Type—To extend our inquiry into the role
of PKCII as the regulator of Ser-473 phosphorylation, we next
stimulated mast cells with SCF or IL-3, two major mast cell
growth factors. In contrast with FcRI stimulation (Fig. 3a),
SCF and IL-3 induced robust Ser-473 phosphorylation in
PKC/ cells similar to that observed in wt cells (Fig. 6a).
When splenic T and B cells were stimulated with anti-CD3/
anti-CD28 and anti- monoclonal antibodies, respectively, Akt
was phosphorylated on Ser-473 at similar levels in wt and
FIG. 3. Ser-473 phosphorylation and
catalytic activity of Akt are depend-
ent on PKC. wt and PKC/ BMMC
or SCF-FLMC were sensitized overnight
with anti-DNP IgE and stimulated by the
indicated concentrations (a) or otherwise
100 ng/ml DNP-human serum albumin
for the indicated periods. Cell lysates
were analyzed by immunoblotting with
anti-Akt(pS473) (a) or anti-GSK-3 (pS21)
(d) antibody. The blots were reprobed
with anti-Akt (a) or anti-GSK-3 (d). b
and c, anti-Akt immunoprecipitates from
IgE/antigen-stimulated BMMC were sub-
jected to kinase assays using recombinant
BAD (b) or Crosstide (c) as substrate. Ag,
antigen.
FIG. 4. Akt Ser-473 phosphorylation is largely dependent on PKCII in FcRI-stimulated mast cells. a and b, PKC/ BMMC
transduced with wt or KD (K/R) PKCI or PKCII were analyzed by immunoblotting consecutively with anti-Akt(pT308) (a) or anti-Akt(pS473)
(b) and anti-Akt. Wt and PKC/ BMMC cultured in the presence of SCF for2 weeks were analyzed in parallel (a and b). Representative results
from three sets of transduced cells are shown. c, wt and PKC/ BMMC transduced with HA-tagged wt, KD (K179M), or T308A Akt were
stimulated with IgE and antigen. Cells were analyzed for Ser-473 phosphorylation of HA-tagged Akt. The blots were reprobed with anti-HA. A
representative result of three experiments is shown. Ag, antigen.
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PKC/ mice (Fig. 6b and data not shown). When mouse
embryonic fibroblasts were stimulated with serum, we ob-
served similarly robust Ser-473 phosphorylation in wt and
PKC/ cells (Fig. 6c). These results indicate that there
must exist multiple kinases that have PDK2 or Ser-473 kinase
activity.
DISCUSSION
Unlike PDK1 that was extensively characterized, the iden-
tity of PDK2 has been enigmatic. Three classes of PDK2 can-
didates have been proposed (10): 1) several distinct kinases
including ILK, 2) peptide-induced conversion of PDK1 to PDK2
(30), and 3) Ser-473 autophosphorylation following Thr-308
phosphorylation (13). However, none of these hypotheses could
fully explain the PDK2 activity in several cellular systems.
Recent reports suggested that a constitutively active PDK2
distinct from ILK, PDK1, or Akt is localized to the plasma
membrane (4, 26, 31) and is resistant to staurosporine (32, 33).
In one study, PDK2 activity was found in a complex with PKC
(33). By contrast, Ser-473 phosphorylation in FcRI-stimulated
mast cells was staurosporine-sensitive (supplementary Fig.
S3b), and PKC was not found in Akt immune complexes from
mast cell lysates (Fig. 1b). Our data also demonstrate that
defects in Ser-473 phosphorylation in PKC-deficient mast
cells are partial (up to 80% reduction) and depend on cell types
and stimuli. These studies collectively point to the existence of
multiple PDK2 enzymes.
Our data in favor of the hypothesis that PKCII serves as a
major PDK2 in FcRI-stimulated mast cells are extensive.
First, PMA could induce Akt phosphorylation on Ser-473. Sec-
ond, PKCII was physically associated with Akt, and this as-
sociation was direct and augmented upon FcRI stimulation.
Third, consistent with previous studies that Ser-473 phospho-
rylation takes place at the plasma membrane (7), a substantial
fraction of PKCII was membrane-associated in mast cells.
Fourth, PKCII could phosphorylate Akt on Ser-473, and en-
zymatic kinetics of S473tide phoshorylation by PKCII were
similar to those of T308tide phosphorylation by PDK1. Fifth,
Ser-473 phosphorylation was impaired in FcRI-stimulated
PKC/ mast cells and this phosphorylation was restored by
reconstitution with PKCII. Sixth, Ser-473 phosphorylation of
the HA-tagged KD Akt was almost abrogated in FcRI-stimu-
lated PKC/ mast cells (Fig. 4c), whereas it was nearly
intact in wt cells, excluding the possibility of Akt autophospho-
rylation as the major mechanism for Ser-473 phosphorylation.
A residual and delayed Ser-473 phosphorylation of HA-tagged
KD Akt in FcRI-stimulated PKC/ cells (Fig. 4c) could be
due to other PDK2 activities or a residual autophosphorylating
activity of the mutant Akt, although the latter possibility is less
likely given the lack of kinase activity of K179M Akt (34).
Our in vitro results indicate that PKC has a PDK2 activity.
However, the extremely low Ser-473 phosphorylation of HA-
tagged KD Akt in PKC/ mast cells and the results with
PKC small interfering RNA and Go¨-6976 indicate that the
role of PKC (40 ng/106 cells) as PDK2 is at best minor in
FcRI-stimulated mast cells. This could be due to a much lower
ratio of membrane versus cytosolic PKC (0.5%) compared
with that of PKCII (20–70%; 50 ng/106 cells) (Ref. 23 and data
not shown). Deficiency of PKC (8 ng/106 cells) or PKC (0.05
ng/106 cells) did not affect Ser-473 phosphorylation. Expression
levels of the other novel or atypical PKC isoforms in BMMC are
less than 1 ng per 106 cells (data not shown). Another kinase
with PDK2 activity in mast cells might be ILK, which was
detected at a low level in Akt immunoprecipitates. However,
FIG. 5. Reconstitution with PKCII can restore degranulation
and IL-2 secretion in IgE/antigen-stimulated PKC/ mast
cells. PKC/ BMMC were transfected with retroviral vectors encod-
ing wild-type or KD (K/R) PKCI or PKCII. Drug-selected mass
cultured transfectants were stimulated with IgE and antigen. Culture
supernatants of IgE-sensitized transfectants stimulated with the indi-
cated concentrations of antigen for 45 min (a) and 20 h (b) were used to
measure histamine (a) and IL-2 (b). Representative results from three
sets of transfectants are shown. The other two sets of transfectants
exhibited similar results.
FIG. 6. Akt Ser-473 phosphorylation does not require PKC in
IL-3- or SCF-stimulatedmast cells or other cellular situations. a,
growth factor-starved wt and PKC/ BMMC were incubated with
100 ng/ml recombinant mouse IL-3 (upper two panels) or 100 ng/ml
recombinant mouse SCF (lower two panels) for the indicated periods. b,
splenic T cells from wt and PKC/ mice were stimulated by anti-
CD3 and anti-CD28. c, embryonic fibroblasts from wt and PKC/
mice (MEF) were stimulated with 20% fetal calf serum for the indicated
periods. Cell lysates were analyzed for Ser-473 phosphorylation and
Akt amounts.
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ILK activity was not reduced in PKC/ mast cells (data not
shown). Overall, these data favor the hypothesis that PKCII
is a major PDK2 in FcRI-activated mast cells.
This study demonstrates that Akt Ser-473 phosphorylation
is regulated by PKCII in a cell type/stimulus-specific manner
and suggests that there are multiple Ser-473 kinases that are
used in a cell type/stimulus-specific manner. This is in stark
contrast with Thr-308 phosphorylation, which is executed by
an evolutionally conserved kinase PDK1 regardless of stimuli
that elicit phosphatidylinositol 3-kinase activation. These re-
sults may provide a foundation to search for compounds that
inhibit PKCII or other kinase(s) that function as a cell type/
stimulus-specific PDK2. Akt is implicated in the pathogenesis
of various cancers and diabetes. Inhibition of a cell type/stim-
ulus-specific regulator of Akt rather than that of the phosphati-
dylinositol 3-kinase/PDK1 arm of Akt activators may broaden
our choices of strategies to treat these diseases.
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